EUVIMEDOpdag EUVIMED
KohortenstudieOpen access

Association Between Ursodeoxycholic Acid and Clinical Outcomes in Patients With COVID-19 Infection: Population-Based Cohort Study

Hyunjun Lee iD, Min Gul Kim iD, Sang Woo Yeom iD, Sang Jae Noh iD, Cho Yun Jeong iD, Min Ji Kim iD, Min Gu Kang iD, Ji Hoon Ko iD, Su Cheol Park iD, Hyeok Tae Kweon iD, Sang Il Sim iD, Hyun Lee iD and 2 more

JMIR Public Health and Surveillance · 2024-10-07 · 10 · e59274

DOI: 10.2196/59274 ↗

At a glance

Kohortenstudie in JMIR Public Health and Surveillance, published online on 2024-10-07. Written by Hyunjun Lee and 13 co-authors. Institution: Department of Otorhinolaryngology-Head and Neck Surgery, Jeonbuk National University Medical School, Jeonju, Republic of Korea, Jeonju, Republic of K…. Major MEDLINE topics: Ursodeoxycholic Acid, COVID-19. Cited 6 times so far (Crossref); 36 references. The full text is freely available in PubMed Central.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Background

Several studies have investigated the relationship between ursodeoxycholic acid (UDCA) and COVID-19 infection. However, complex and conflicting results have generated confusion in the application of these results.

Objective

We aimed to investigate whether the association between UDCA and COVID-19 infection can also be demonstrated through the analysis of a large-scale cohort.

Methods

This retrospective study used local and nationwide cohorts, namely, the Jeonbuk National University Hospital into the Observational Medical Outcomes Partnership common data model cohort (JBUH CDM) and the Korean National Health Insurance Service claim–based database (NHIS). We investigated UDCA intake and its relationship with COVID-19 susceptibility and severity using validated propensity score matching.

Results

Regarding COVID-19 susceptibility, the adjusted hazard ratio (aHR) value of the UDCA intake was significantly lowered to 0.71 in the case of the JBUH CDM (95% CI 0.52-0.98) and was significantly lowered to 0.93 (95% CI 0.90-0.96) in the case of the NHIS. Regarding COVID-19 severity, the UDCA intake was found to be significantly lowered to 0.21 (95% CI 0.09-0.46) in the case of JBUH CDM. Furthermore, the aHR value was significantly lowered to 0.77 in the case of NHIS (95% CI 0.62-0.95).

Conclusions

Using a large-scale local and nationwide cohort, we confirmed that UDCA intake was significantly associated with reductions in COVID-19 susceptibility and severity. These trends remained consistent regardless of the UDCA dosage. This suggests the potential of UDCA as a preventive and therapeutic agent for COVID-19 infection.

Subjects

MeSH terms (MEDLINE)

Ursodeoxycholic AcidCOVID-19HumansMaleFemaleMiddle AgedRetrospective StudiesRepublic of KoreaAdultAgedCohort StudiesCOVID-19 Drug TreatmentTreatment OutcomeSeverity of Illness Index

Author keywords

COVID-19CoronavirusCovid 19SARS-CoV-2UDCAclinicalcommon data modelpandemicpopulation-basedpopulation-based cohort studypropensity scorepublic healthretrospective cohort studyseverityursodeoxycholic acid

Substances

Ursodeoxycholic Acid

Authors and institutions

  • Department of Otorhinolaryngology-Head and Neck Surgery, Jeonbuk National University Medical School, Jeonju, Republic of Korea, Jeonju, Republic of Korea.
  • Department of Pharmacology, Jeonbuk National University Medical School, Jeonju, Republic of Korea, Jeonju, Republic of Korea.
  • Department of Medical Informatics, Jeonbuk National University Medical School, Jeonju, Republic of Korea, Jeonju, Republic of Korea.
  • Research Institute of Clinical Medicine of Jeonbuk National University-Biomedical Research Institute of Jeonbuk National University Hospital, Jeonju, Republic of Korea, Jeonju, Republic of Korea.
  • Big Data Center, Jeonbuk National University Hospital, Jeonju, Republic of Korea.
  • Department of Internal Medicine, Hanyang University College of Medicine, Seoul, Republic of Korea.

ORCID profiles: Hyunjun Lee, Min Gul Kim, Sang Woo Yeom, Sang Jae Noh, Cho Yun Jeong, Min Ji Kim, Min Gu Kang, Ji Hoon Ko, Su Cheol Park, Hyeok Tae Kweon, Sang Il Sim, Hyun Lee, Yeon Seok You, Jong Seung Kim

Cite

APA

Lee, H., Kim, M. G., Yeom, S. W., Noh, S. J., Jeong, C. Y., Kim, M. J., Kang, M. G., Ko, J. H., Park, S. C., Kweon, H. T., Sim, S. I., Lee, H., You, Y. S., & Kim, J. S. (2024). Association Between Ursodeoxycholic Acid and Clinical Outcomes in Patients With COVID-19 Infection: Population-Based Cohort Study. JMIR Public Health and Surveillance, 10, e59274. https://doi.org/10.2196/59274

Vancouver

Lee H, Kim MG, Yeom SW, Noh SJ, Jeong CY, Kim MJ, et al. Association Between Ursodeoxycholic Acid and Clinical Outcomes in Patients With COVID-19 Infection: Population-Based Cohort Study. JMIR Public Health and Surveillance. 2024;10:e59274. doi:10.2196/59274

BibTeX
@article{Lee2024,
  author = {Lee, Hyunjun and Kim, Min Gul and Yeom, Sang Woo and Noh, Sang Jae and Jeong, Cho Yun and Kim, Min Ji and Kang, Min Gu and Ko, Ji Hoon and Park, Su Cheol and Kweon, Hyeok Tae and Sim, Sang Il and Lee, Hyun and You, Yeon Seok and Kim, Jong Seung},
  title = {Association Between Ursodeoxycholic Acid and Clinical Outcomes in Patients With COVID-19 Infection: Population-Based Cohort Study},
  journal = {JMIR Public Health and Surveillance},
  year = {2024},
  volume = {10},
  pages = {e59274},
  doi = {10.2196/59274}
}
Start for free →